Syntara to start Phase 2 study targeting MDS
–News Direct–
Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactives Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS).
Phillips highlighted the significance of SNT-5505 in addressing MDS, a complex condition, underscoring the drug's potential impact on patient care.
The company is collaborating with several partners in a strategic move that fosters local partnerships to advance the research.
From a commercial standpoint, this development represents a pivotal advancement for Syntara, as it embarks on its fourth concurrent Phase 2 study, balancing the demands of cash flow and timelines effectively.
Looking ahead, Phillips hinte...